RCC

17 clinical trials · Condition

Record	Firm	Date
Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors (NCT03875313)	Calithera Biosciences, Inc	2019-05-20
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies (NCT03652077)	Incyte Corporation	2018-09-24
Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma (NCT03035630)	Guru Sonpavde	2017-05-23
A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001) (NCT02974738)	Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	2016-12-07
Nivolumab in mRCC Patients: Treg Function, T-cell Access and NK Interactions to Predict and Improve Efficacy (NCT03891485)	National Cancer Institute, Naples	2016-12-01
Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma (mRCC) (NCT02447887)	Fox Chase Cancer Center	2015-08-14
A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001) (NCT02293980)	Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	2014-11-25
Phase II Study of Anlotinib Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma（RCC） (NCT02072031)	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	2013-12-01

Every clearance here is in the API, with alerts when new ones post.